Wednesday 1st December 2010, 10.00-16.00
Location: London, Venue TBC
This workshop will encourage engagement between the National Institute for Health and Clinical Excellence (NICE) and industry experts with an interest in developing and manufacturing clinically relevant diagnostic devices within the scope of the Detection & Identification of Infectious Agents (DIIA) Innovation Platform.
The Technology Strategy Board’s Innovation Platform, DIIA, aims to reduce the morbidity, mortality and economic burden of infectious diseases in humans and animals. The programme will see investment of up to £55 million over 5 years - up to £50 million from the Technology Strategy Board and up to £5 million from the Department of Health (DH).
DIIA is now looking to facilitate dialogue between the diagnostics industrial community and NICE with particular reference to the role of NICE in diagnostic system evaluation.
The workshop will also allow companies that are on track towards diagnostic system manufacture to engage early with NICE in an informal and supportive environment.
Draft Agenda
10.00
|
Welcome and opening remarks
|
|
10.10
|
Aims of meeting
|
Penny Wilson, Technology Strategy Board
|
10.40
|
Diagnostics for The Real World
|
Helen Lee, Associate Professor and Reader in Medical Biotechnology, Cambridge University
|
11.00
|
Atlas Genetics
|
John Clarkson, CEO
|
11.20
|
Lumora Ltd
|
Laurence Tisi, CEO
|
11.40
|
Roche Diagnostics
|
John Burling, Director of Regulatory Affairs
|
12.00
|
|
|
12.20
|
Discussion
|
|
12.50
|
Lunch
|
|
14.00
|
NICE
|
Carole Longson
|
14.30
|
NICE
|
Nick Crabb
|
15.00
|
Discussion
|
|
16.00
|
Close
|
|
If you would like to attend this meeting please reply to sarah.forson@twi.co.uk
You need to be a member of Life Sciences Scotland to add comments!
Join Life Sciences Scotland